# US 2020/0002394 A1 · Hdm-2 targeting compositions cause tumor cell necrosis rather than apoptosis of cancer cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0002394 A1
- Document ID: US20200002394A1
- Status: Published application
- Kind: A1
- Application number: 16/556,623
- Filed: 2019-08-30
- Published: 2020-01-02
- Earliest claimed: 2008-10-03
- Assignees: The Research Foundation of State University of New York
- Applicants: The Research Foundation of State University of New York
- Inventors: Matthew R. Pincus; Josef Michl; Ehsan Sarafraz-Yazdi
- Web page: https://patentgrep.com/patent/US20200002394A1

## CPC

- C07K 14/4746: {p53}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- A61K 38/02: Peptides of undefined number of amino acids; Derivatives thereof
- C07K 2/00: Peptides of undefined number of amino acids; Derivatives thereof
- G01N 2333/4748: p53
- G01N 2333/904: acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
- G01N 2500/10: involving cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

An aspect of the invention provides a method of selectively necrosing cells, comprising: providing a plurality cells, including at least one cancer cell and at least one non-cancerous cell; and administering to the cells a compound, including an HDM-2 targeting component and a cytotoxic component attached to the HDM-2 targeting component, wherein said compound comprises a membrane-active form.

## Claims

### Claim 1

A method of selectively necrosing cells, comprising:
providing a plurality cells, including at least one cancer cell and at least one non-cancerous cell;
administering to the cells a compound, including an HDM-2 targeting component and a cytotoxic component, said cytotoxic component attached to said HDM-2 targeting component, wherein said compound comprises a membrane-active form.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cytotoxic component is selected from the group consisting of: a membrane resident peptide, a toxin, a drug, a radionuclide, a whole antibody, an antibody fragment, and combinations thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the HDM-2 targeting component is selected from the group consisting of: a small molecule, a peptide, a protein, a glycoprotein, a whole antibody, an antibody fragment, and combinations thereof.

### Claim 4 (depends on 1)

The method of claim 1, further comprising the step of observing in a cell medium a level of LDH.

### Claim 5 (depends on 1)

The method of claim 1, further comprising the step of observing necrosis in the cancer cells.

### Claim 6 (depends on 1)

The method of claim 1, further comprising the step of observing a non-response in the non-cancerous cell, wherein the non-response indicates the non-cancerous cell is unaffected.

### Claim 7 (depends on 1)

The method of claim 1, wherein the administering step further comprises administering a PNC-27, a PNC-28 peptide, or combinations thereof.

### Claim 8

A method of causing membranolysis in at least one cancer cell, comprising:
administering to at least one cancer cell a compound comprising an HDM-2 targeting component and a pore-forming component attached to said HDM-2 targeting component, wherein said administering step results in at least one transmembrane pore in a cancer cell membrane.

### Claim 9 (depends on 8)

The method of claim 8, further wherein the administering step further comprises administering said compound at a dosage.

### Claim 10 (depends on 8)

The method of claim 8, further comprising the step of observing membranolysis in the cancer cell by: detecting an LDH amount, performing electron microscopy, observing cell morphology, and combinations thereof.

### Claim 11 (depends on 8)

The method of claim 8, further comprising the step of observing necrosis of the cancer cell.

### Claim 12

A method of treating cancer in a subject in need thereof, comprising:
administering to the subject in need thereof a therapeutically effective amount of a compound having an HDM-2 targeting component and a cytotoxic component, said HDM-2 targeting component and said cytotoxic component having a membrane-active form.

### Claim 13 (depends on 12)

The method of claim 12, wherein the cytotoxic component is selected from the group consisting of: a membrane resident peptide, a toxin, a drug, a radionuclide, a whole antibody, an antibody fragment, and combinations thereof.

### Claim 14 (depends on 12)

The method of claim 12, wherein the HDM-2 targeting component is selected from the group consisting of: a small molecule, a peptide, a protein, a glycoprotein, a whole antibody, an antibody fragment, and combinations thereof.

### Claim 15 (depends on 12)

The method of claim 12 further comprising the step of determining whether a plurality of cancerous cells have undergone membranolysis.

### Claim 16 (depends on 12)

The method of claim 12, further comprising the step of, after the administering step, determining whether a plurality subsequent cancer cells exists.

### Claim 17

A method of screening cancer treatments, comprising:
providing a plurality of cancerous cells; each of said cells having HDM-2 in said cellular membranes;
administering a candidate cancer treatment to the plurality of cancer cells; and
measuring the level of LDH present in a cellular medium.

### Claim 18 (depends on 17)

The method of claim 17, further comprising the step of determining whether the candidate cancer treatment has membrane active conformation.

### Claim 19 (depends on 17)

The method of claim 17, further comprising the step of determining whether the candidate cancer treatment includes an HDM-2 targeting component.

### Claim 20 (depends on 17)

The method of claim 17, further comprising the step of observing the cancer cell membranes for an area of pore formation.

### Claim 21

A method of selectively necrosing cancer cells, comprising:
providing a plurality of cells, including at least one cancer cell and at least one non-cancerous cell; and
contacting the plurality of cells with an HDM-2 targeting compound which includes a membrane resident peptide (MRP), wherein the HDM-2 targeting compound colocalizes to HDM-2 present in at least one cancer cell membrane, binding to a cell membrane of the at least one cancer cell and adopting a membrane-resident conformation within said cancer cell membrane.

### Claim 22 (depends on 21)

The method of claim 21, wherein adopting the membrane-resident conformation further includes forming a pore in said cancer cell membrane.

### Claim 23 (depends on 21)

The method of claim 21, comprising observing necrosis in the plurality of cancer cells.

### Claim 24 (depends on 21)

The method of claim 21, comprising observing a non-result in the non-cancerous cells, indicative of non-targeting of said non-cancerous cells.

### Claim 25

A method of identifying cancer cells, comprising:
providing a plurality of cells, wherein at least one of said cells is a candidate cancer cell; and
administering to the plurality of cells an HDM-2 recognition agent.

### Claim 26 (depends on 25)

The method of claim 25, further comprising of the step of observing the plurality of cells for the HDM-2 recognition agent colocalization with at least one cell membrane.

### Claim 27 (depends on 25)

The method of claim 25, wherein said HDM-2 recognition agent further comprises an HDM-2 targeting component tagged with an observation aid, said observation aid selected from the group consisting of: a dye, an enzyme, a fluorescing agent, a radiopaque material, a radioactive isotope and combinations thereof.

### Claim 28 (depends on 25)

The method of claim 25, further comprising indentifying at least one cancer cell.

### Claim 29 (depends on 25)

The method of claim 25, further comprising mapping a plurality of cancer cells.
